ClinicalTrials.gg
CompletedNCT04233879Updated Jun 3, 2026Results posted

Study of Doravirine/Islatravir (DOR/ISL 100 mg/0.75 mg) to Evaluate the Antiretroviral Activity, Safety, and Tolerability in Treatment-Naïve Participants With Human Immunodeficiency Virus Type 1 (HIV-1) Infection (MK-8591A-020)

A Phase 3 interventional study of DOR/ISL and BIC/FTC/TAF in HIV-1 Infection, sponsored by Merck Sharp & Dohme LLC. Completed at 95 sites in 13 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-03.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
599
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a phase 3, randomized, controlled, double-blind, multisite clinical study of a once-daily fixed dose combination (FDC) of 100 mg doravirine/0.75 mg islatravir (DOR/ISL [also known as MK-8591A]) in treatment-naïve participants living with human immunodeficiency virus type-1 (HIV-1) infection. The primary objectives are to evaluate the antiretroviral activity, safety, and tolerability of DOR/ISL compared to bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF). The primary hypothesis is that DOR/ISL is noninferior or superior to BIC/FTC/TAF treatment based on the percentage of participants with HIV-1 ribonucleic acid (RNA) \<50 copies/mL at Week 48.

Read the detailed description

Double-blind treatment with the assigned intervention occurs from Day 1 to Week 96, followed by an open-label portion up to Week 144. Participants who benefit from treatment in the opinion of the Investigator may continue their assigned intervention up to Week 168 (or until they have the option to enroll in a DOR/ISL 100 mg/0.25 mg study, whichever is sooner).

02

Conditions studied

  • HIV-1 Infection
03

In context

Lead sponsor

Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.

Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Is type 1 (HIV-1) positive
  • Is naïve to antiretroviral therapy (ART) defined as having received ≤10 days of prior therapy with any antiretroviral agent following a diagnosis of HIV-1 infection including prevention of mother-to-child transmission up to 1 month prior to screening.
  • A female participant is eligible to participate if she is not pregnant or breastfeeding, and at least one of the following conditions applies: 1) Is not a woman of (WOCBP); 2) Is a WOCBP and using an acceptable method, or be abstinent from heterosexual intercourse as their preferred and usual lifestyle (abstinent on a long term and persistent basis); 3) A WOCBP must have a negative highly sensitive pregnancy test ([urine or serum] as required by local regulations) within 24 hours before the first dose of study intervention; 4) If a urine test cannot be confirmed as negative (eg, an ambiguous result), a serum pregnancy test is required

Exclusion criteria

Exclusion Criteria:

  • Has type 2 (HIV-2) infection
  • Has or other to any of the components of the study interventions as determined by the investigator
  • Has an active diagnosis of hepatitis due to any cause, including active virus (HBV) infection (defined as hepatitis B surface antigen [HBsAg]-positive or hepatitis B virus deoxyribonucleic acid [HBV DNA]-positive)
  • Has a history of ≤5 years prior to signing except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or cutaneous Kaposi's sarcoma
  • Has a history or current evidence of any condition (including active tuberculosis infection), therapy, laboratory abnormality or other circumstance (including drug or alcohol use or dependence) that might, in the opinion of the investigator, confound the results of the study or interfere with the participant's participation for the full duration of the study
  • Has been treated for a viral infection other than HIV-1, such as hepatitis B, with an agent that is active against HIV-1
  • Is taking or is anticipated to require systemic therapy, immune modulators, or any prohibited therapy from 45 days prior to Day 1 through the study intervention period
  • Is currently participating in or has participated in a clinical study with an compound or device from 45 days prior to Day 1 through the study intervention period
  • Has a documented or known virologic resistance to any approved HIV-1 reverse transcriptase inhibitor, or any study intervention
  • Has exclusionary laboratory values within 45 days prior to Day 1
  • Is female and is expecting to conceive or donate eggs at any time during the study
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
599 participants (actual)

Study arms

  • Experimental
    Group 1: doravirine/islatravir (DOR/ISL)

    Treatment-naïve participants living with human immunodeficiency virus-1 (HIV-1) that had not received ≤10 days of prior antiretroviral therapy received blinded fixed dose combination (FDC) Doravirine/Islatravir (DOR/ISL) (100 mg doravirine \[DOR\]/0.75 mg islatravir \[ISL\]) and placebo to Bictegravir/Tenofovir Alafenamide/Emtricitabine (BIC/FTC/TAF) once daily (QD) from Day 1 to Week 96, and open-label DOR/ISL up to Week 144. At Week 144, participants who consent to enter the optional open-label study extension continued to receive open-label QD FDC of DOR/ISL (100 mg/0.75 mg) for an additional 24 weeks, up to Week 168.

    Drug: DOR/ISL · Drug: Placebo to BIC/FTC/TAF

  • Active comparator
    Group 2: bictegravir/emtricitabine/tenofovir alafenamide (BIC/FTC/TAF)

    Treatment-naïve participants living with HIV-1 that had not received ≤10 days of prior antiretroviral therapy received blinded BIC/FTC/TAF (50 mg bictegravir \[BIC\], 200 mg emtricitabine \[FTC\], 25 mg tenofovir alafenamide \[TAF\]) and placebo to FDC DOR/ISL QD from Day 1 to Week 96, and open-label BIC/FTC/TAF up to Week 144. At Week 144, participants who consent to enter the optional open-label study extension continued to receive QD BIC/FTC/TAF (50 mg/200 mg/25 mg) for an additional 24 weeks, up to Week 168.

    Drug: BIC/FTC/TAF · Drug: Placebo to DOR/ISL

Interventions

  • DrugDOR/ISL

    Drug pages: Doravirine · Islatravir

    100 mg DOR/0.75 mg ISL FDC single tablet taken once daily by mouth.

    Also known as: MK-8591A, Doravirine/islatravir

  • DrugBIC/FTC/TAF

    Drug pages: Bictegravir · Emtricitabine · Tenofovir alafenamide

    BIC/FTC/TAF 50/200/25 mg FDC single tablet taken once daily by mouth.

    Also known as: Bictegravir/emtricitabine/tenofovir alafenamide

  • DrugPlacebo to BIC/FTC/TAF

    Placebo single tablet matched to BIC/FTC/TAF taken by mouth.

  • DrugPlacebo to DOR/ISL

    Placebo single tablet matched to DOR/ISL taken by mouth.

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Human Immunodeficiency Virus (HIV)-1 Ribonucleic Acid (RNA) <50 Copies/mL at Week 48

    The Abbott RealTime polymerase chain reaction (PCR) assay with a reliable lower limit of quantification of 40 copies/mL was used to measure the HIV-1 RNA level in blood samples obtained at each visit. The percentage of participants with HIV-1 RNA \<50 copies/mL at Week 48 was presented using the Food and Drug Administration (FDA) Snapshot missing data approach. The final analysis for this outcome is presented here.

    Time frame: Week 48

  2. Percentage of Participants Who Experienced an Adverse Event (AE) up to Week 48

    An AE was any untoward medical occurrence in a study participant administered a study drug, which does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of the study drug whether or not it is considered related to the study drug. The percentage of participants who experienced at least one AE up to Week 48 was reported. The final analysis for this outcome is presented here.

    Time frame: Up to approximately 48 weeks

  3. Percentage of Participants Who Discontinued Study Treatment Due to an AE up to Week 48

    An AE was any untoward medical occurrence in a study participant administered a study drug, which does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of the study drug whether or not it is considered related to the study drug. The percentage of participants who discontinued study treatment due to an AE up to Week 48 were reported. The final analysis for this outcome is presented here.

    Time frame: Up to approximately 48 weeks

Secondary outcomes

  1. Percentage of Participants With HIV-1 RNA <50 Copies/mL at Week 96

    The Abbott RealTime PCR assay with a reliable lower limit of quantification of 40 copies/mL was used to measure the HIV-1 RNA level in blood samples obtained at each visit. The percentage of participants with HIV-1 RNA \<50 copies/mL at Week 96 was presented using the FDA Snapshot missing data approach. The final analysis for this outcome is presented here.

    Time frame: Week 96

  2. Percentage of Participants With HIV-1 RNA <50 Copies/mL at Week 144

    The Abbott RealTime PCR assay with a reliable lower limit of quantification of 40 copies/mL was used to measure the HIV-1 RNA level in blood samples obtained at each visit. The percentage of participants with HIV-1 RNA \<50 copies/mL at Week 144 was presented using the Data as Observed (DAO) missing data approach. The final analysis for this outcome is presented here.

    Time frame: Week 144

  3. Percentage of Participants With HIV-1 RNA <40 Copies/mL at Week 48

    The percentage of participants with HIV-1 RNA \<40 copies/mL was determined. The Abbott RealTime PCR assay with a reliable lower limit of quantification of 40 copies/mL was used to measure the HIV-1 RNA level in blood samples obtained at each visit. The percentage of participants with HIV-1 RNA \<40 copies/mL at Week 48 was presented using the FDA Snapshot missing data approach. The final analysis for this outcome is presented here.

    Time frame: Week 48

  4. Percentage of Participants With HIV-1 RNA <200 Copies/mL at Week 48

    The percentage of participants with HIV-1 RNA \<200 copies/mL was determined. The Abbott RealTime PCR assay with a reliable lower limit of quantification of 40 copies/mL was used to measure the HIV-1 RNA level in blood samples obtained at each visit. The percentage of participants with HIV-1 RNA \<200 copies/mL at Week 48 was presented using the FDA Snapshot missing data approach. The final analysis for this outcome is presented here.

    Time frame: Week 48

  5. Percentage of Participants With HIV-1 RNA <40 Copies/mL at Week 96

    The Abbott RealTime PCR assay with a reliable lower limit of quantification of 40 copies/mL was used to measure the HIV-1 RNA level in blood samples obtained at each visit. The percentage of participants with HIV-1 RNA \<40 copies/mL at Week 96 was presented using the FDA Snapshot missing data approach. The final analysis for this outcome is presented here.

    Time frame: Week 96

  6. Percentage of Participants With HIV-1 RNA <200 Copies/mL at Week 96

    The Abbott RealTime PCR assay with a reliable lower limit of quantification of 40 copies/mL was used to measure the HIV-1 RNA level in blood samples obtained at each visit. The percentage of participants with HIV-1 RNA \<200 copies/mL at Week 96 was presented using the FDA Snapshot missing data approach. The final analysis for this outcome is presented here.

    Time frame: Week 96

  7. Percentage of Participants With HIV-1 RNA <40 Copies/mL at Week 144

    The Abbott RealTime PCR assay with a reliable lower limit of quantification of 40 copies/mL was used to measure the HIV-1 RNA level in blood samples obtained at each visit. The percentage of participants with HIV-1 RNA \<40 copies/mL at Week 144 was presented using the DAO missing data approach. The final analysis for this outcome is presented here.

    Time frame: Week 144

  8. Percentage of Participants With HIV-1 RNA <200 Copies/mL at Week 144

    The Abbott RealTime PCR assay with a reliable lower limit of quantification of 40 copies/mL was used to measure the HIV-1 RNA level in blood samples obtained at each visit. The percentage of participants with HIV-1 RNA \<200 copies/mL at Week 144 was presented using the DAO missing data approach. The final analysis for this outcome is presented here.

    Time frame: Week 144

  9. Mean Change From Baseline in Cluster of Differentiation 4+ (CD4+) T-Cell Counts at Week 48

    Plasma CD4+ T-cell count was measured in cells/mm\^3 for baseline and at Week 48 by a central laboratory. Baseline measurements were defined as the Day 1 value of each participant. The mean change from baseline in CD4+ T-cell count at Week 48 using the Data as Observed (DAO) approach was presented. The final analysis for this outcome is presented here.

    Time frame: Baseline (Day 1) and Week 48

  10. Mean Change From Baseline in Cluster of Differentiation 4+ (CD4+) T-Cell Counts at Week 96

    Plasma CD4+ T-cell count was measured in cells/mm\^3 for baseline and at Week 96 by a central laboratory. Baseline measurements were defined as the Day 1 value of each participant. The mean change from baseline in CD4+ T-cell count at Week 96 using the Data as Observed (DAO) approach was presented. The final analysis for this outcome is presented here.

    Time frame: Baseline (Day 1) and Week 96

  11. Mean Change From Baseline in Cluster of Differentiation 4+ (CD4+) T-Cell Counts at Week 144

    Plasma CD4+ T-cell count was measured in cells/mm\^3 for baseline and at Week 144 by a central laboratory. Baseline measurements were defined as the Day 1 value of each participant. The mean change from baseline in CD4+ T-cell count at Week 144 using the Data as Observed (DAO) approach was presented. The final analysis for this outcome is presented here.

    Time frame: Baseline (Day 1) and Week 144

  12. Incidence of Viral Resistance-Associated Substitutions (RASs) at Week 48

    RASs was defined as participants with confirmed HIV-1 RNA ≥200 copies/mL and/or genotypic or phenotypic analysis of data showing evidence of resistance to the study drug administered. The number of participants who demonstrated RASs at Week 48 was presented. The final analysis for this outcome is presented here.

    Time frame: Week 48

  13. Incidence of Viral RASs at Week 96

    RASs was defined as participants with confirmed HIV-1 RNA ≥200 copies/mL and/or genotypic or phenotypic analysis of data showing evidence of resistance to the study drug administered. The number of participants who demonstrated RASs at Week 96 was presented. The final analysis for this outcome is presented here.

    Time frame: Week 96

  14. Incidence of Viral RASs at Week 144

    RASs was defined as participants with confirmed HIV-1 RNA ≥200 copies/mL and/or genotypic or phenotypic analysis of data showing evidence of resistance to the study drug administered. The number of participants who demonstrated RASs at Week 144 was presented. The final analysis for this outcome is presented here.

    Time frame: Week 144

  15. Mean Change From Baseline in Body Weight at Week 48

    Body weight was measured at baseline and at Week 48. Participants removed their shoes and wore a single layer of clothing at each measurement. Baseline measurements were defined as the Day 1 value of each participant. The mean change from baseline in body weight at Week 48 was presented. The final analysis for this outcome is presented here.

    Time frame: Baseline (Day 1) and Week 48

  16. Mean Change From Baseline in Body Weight at Week 96

    Body weight was measured at baseline and at Week 96. Participants removed their shoes and wore a single layer of clothing at each measurement. Baseline measurements were defined as the Day 1 value of each participant. The mean change from baseline in body weight at Week 96 was presented. The final analysis for this outcome is presented here.

    Time frame: Baseline (Day 1) and Week 96

  17. Mean Change From Baseline in Body Weight at Week 144

    Body weight was measured at baseline and at Week 144. Participants removed their shoes and wore a single layer of clothing at each measurement. Baseline measurements were defined as the Day 1 value of each participant. The mean change from baseline in body weight at Week 144 was presented. The final analysis for this outcome is presented here.

    Time frame: Baseline (Day 1) and Week 144

  18. Percentage of Participants Who Experienced an Adverse Event (AE)

    An AE was any untoward medical occurrence in a study participant administered a study drug, which does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of the study drug whether or not it is considered related to the study drug. The percentage of participants who experienced at least one or more AEs is presented. Per protocol, pregnancy-related AEs collected for enrolled participants are reported separately and are presented in the AE module. The final analysis for this outcome is presented here.

    Time frame: Up to approximately 47 months

  19. Percentage of Participants Who Discontinued Study Treatment Due to an AE

    An AE was any untoward medical occurrence in a study participant administered a study drug, which does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of the study drug whether or not it is considered related to the study drug. The percentage of participants who discontinued study intervention due to an AE is presented. Per protocol, pregnancy-related AEs collected for enrolled participants are reported separately and are presented in the AE module. The final analysis for this outcome is presented here.

    Time frame: Up to approximately 38 months

07

Results

Posted Nov 21, 2023

Participant flow

Treatment-naïve participants living with Human Immunodeficiency Virus-1 (HIV-1) that had not received ≤10 days of prior antiretroviral therapy were enrolled.

Base Study (Day 1 to Week 144)
Participant flow — Base Study (Day 1 to Week 144)
MilestoneGroup 1: DOR/ISLGroup 2: BIC/FTC/TAF
Started298301
Treated298299
Completed5934
Not completed239267
Withdrew: Death30
Withdrew: Lost to follow-up1617
Withdrew: Physician decision117
Withdrew: Sponsor decision168179
Withdrew: Withdrawal by subject3534
Withdrew: Other630
Extension Study (Week 144 to 168)
Participant flow — Extension Study (Week 144 to 168)
MilestoneGroup 1: DOR/ISLGroup 2: BIC/FTC/TAF
Started2127
Completed01
Not completed2126
Withdrew: Lost to follow-up01
Withdrew: Sponsor decision2025
Withdrew: Withdrawal by subject10

Outcome measures

PrimaryPercentage of Participants With Human Immunodeficiency Virus (HIV)-1 Ribonucleic Acid (RNA) <50 Copies/mL at Week 48

The Abbott RealTime polymerase chain reaction (PCR) assay with a reliable lower limit of quantification of 40 copies/mL was used to measure the HIV-1 RNA level in blood samples obtained at each visit. The percentage of participants with HIV-1 RNA \<50 copies/mL at Week 48 was presented using the Food and Drug Administration (FDA) Snapshot missing data approach. The final analysis for this outcome is presented here.

Time frame:
Week 48
Reported as:
Number · Percentage of participants
Percentage of Participants With Human Immunodeficiency Virus (HIV)-1 Ribonucleic Acid (RNA) <50 Copies/mL at Week 48
Percentage of participantsGroup 1: DOR/ISLGroup 2: BIC/FTC/TAF
Percentage of Participants With Human Immunodeficiency Virus (HIV)-1 Ribonucleic Acid (RNA) <50 Copies/mL at Week 4888.988.3
Statistical analysis
  • Group 1: DOR/ISL vs Group 2: BIC/FTC/TAF · Treatment difference: 0.46 · 95% CI -4.73 to 5.60Estimated differences, CIs, \& p-value for treatment differences in percent response were calculated using Miettinen \& Nurminen method stratified by stratum with CMH weights; multiplicity-adjusted 95% CI corresponds to 1-sided Type 1 error of 0.02495
PrimaryPercentage of Participants Who Experienced an Adverse Event (AE) up to Week 48

An AE was any untoward medical occurrence in a study participant administered a study drug, which does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of the study drug whether or not it is considered related to the study drug. The percentage of participants who experienced at least one AE up to Week 48 was reported. The final analysis for this outcome is presented here.

Time frame:
Up to approximately 48 weeks
Reported as:
Number · Percentage of participants
Percentage of Participants Who Experienced an Adverse Event (AE) up to Week 48
Percentage of participantsGroup 1: DOR/ISLGroup 2: BIC/FTC/TAF
Percentage of Participants Who Experienced an Adverse Event (AE) up to Week 4890.686.3
Statistical analysis
  • Group 1: DOR/ISL vs Group 2: BIC/FTC/TAF · Percentage difference: 4.3 · 95% CI -0.8 to 9.6Miettinen \& Nurminen method was used to generate percentage difference and the associated 95%CI.
PrimaryPercentage of Participants Who Discontinued Study Treatment Due to an AE up to Week 48

An AE was any untoward medical occurrence in a study participant administered a study drug, which does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of the study drug whether or not it is considered related to the study drug. The percentage of participants who discontinued study treatment due to an AE up to Week 48 were reported. The final analysis for this outcome is presented here.

Time frame:
Up to approximately 48 weeks
Reported as:
Number · Percentage of participants
Percentage of Participants Who Discontinued Study Treatment Due to an AE up to Week 48
Percentage of participantsGroup 1: DOR/ISLGroup 2: BIC/FTC/TAF
Percentage of Participants Who Discontinued Study Treatment Due to an AE up to Week 487.43.3
Statistical analysis
  • Group 1: DOR/ISL vs Group 2: BIC/FTC/TAF · Percentage difference: 4.0 · 95% CI 0.4 to 7.9Miettinen \& Nurminen method was used to generate percentage difference and the associated 95%CI.
SecondaryPercentage of Participants With HIV-1 RNA <50 Copies/mL at Week 96

The Abbott RealTime PCR assay with a reliable lower limit of quantification of 40 copies/mL was used to measure the HIV-1 RNA level in blood samples obtained at each visit. The percentage of participants with HIV-1 RNA \<50 copies/mL at Week 96 was presented using the FDA Snapshot missing data approach. The final analysis for this outcome is presented here.

Time frame:
Week 96
Reported as:
Number · Percentage of participants
Percentage of Participants With HIV-1 RNA <50 Copies/mL at Week 96
Percentage of participantsGroup 1: DOR/ISLGroup 2: BIC/FTC/TAF
Percentage of Participants With HIV-1 RNA <50 Copies/mL at Week 9651.757.9
Statistical analysis
  • Group 1: DOR/ISL vs Group 2: BIC/FTC/TAF · Miettinen and Nurminen method · p = 0.945 (The estimated differences, CIs and p-value for the treatment differences in percent response were calculated using the Miettinen and Nurminen method stratified by stratum with Cochran-Mantel-Haenszel (CMH) weights.) · Estimated difference: -6.42 · 95% CI -14.21 to 1.46Treatment difference for DOR/ISL group minus BIC/FTC/TAF group.
SecondaryPercentage of Participants With HIV-1 RNA <50 Copies/mL at Week 144

The Abbott RealTime PCR assay with a reliable lower limit of quantification of 40 copies/mL was used to measure the HIV-1 RNA level in blood samples obtained at each visit. The percentage of participants with HIV-1 RNA \<50 copies/mL at Week 144 was presented using the Data as Observed (DAO) missing data approach. The final analysis for this outcome is presented here.

Time frame:
Week 144
Reported as:
Number · Percentage of participants
Percentage of Participants With HIV-1 RNA <50 Copies/mL at Week 144
Percentage of participantsGroup 1: DOR/ISLGroup 2: BIC/FTC/TAF
Percentage of Participants With HIV-1 RNA <50 Copies/mL at Week 14464.182.9
Statistical analysis
  • Group 1: DOR/ISL vs Group 2: BIC/FTC/TAF · Estimated difference: -19.5 · 95% CI -38.0 to 0.2Treatment difference for DOR/ISL group minus BIC/FTC/TAF group.
SecondaryPercentage of Participants With HIV-1 RNA <40 Copies/mL at Week 48

The percentage of participants with HIV-1 RNA \<40 copies/mL was determined. The Abbott RealTime PCR assay with a reliable lower limit of quantification of 40 copies/mL was used to measure the HIV-1 RNA level in blood samples obtained at each visit. The percentage of participants with HIV-1 RNA \<40 copies/mL at Week 48 was presented using the FDA Snapshot missing data approach. The final analysis for this outcome is presented here.

Time frame:
Week 48
Reported as:
Number · Percentage of participants
Percentage of Participants With HIV-1 RNA <40 Copies/mL at Week 48
Percentage of participantsGroup 1: DOR/ISLGroup 2: BIC/FTC/TAF
Percentage of Participants With HIV-1 RNA <40 Copies/mL at Week 4888.686.3
Statistical analysis
  • Group 1: DOR/ISL vs Group 2: BIC/FTC/TAF · Treatment difference: 2.12 · 95% CI -3.23 to 7.48The estimated differences, CIs and p-value for the treatment differences in percent response were calculated using the Miettinen and Nurminen method stratified by stratum with Cochran-Mantel-Haenszel (CMH) weights.
SecondaryPercentage of Participants With HIV-1 RNA <200 Copies/mL at Week 48

The percentage of participants with HIV-1 RNA \<200 copies/mL was determined. The Abbott RealTime PCR assay with a reliable lower limit of quantification of 40 copies/mL was used to measure the HIV-1 RNA level in blood samples obtained at each visit. The percentage of participants with HIV-1 RNA \<200 copies/mL at Week 48 was presented using the FDA Snapshot missing data approach. The final analysis for this outcome is presented here.

Time frame:
Week 48
Reported as:
Number · Percentage of participants
Percentage of Participants With HIV-1 RNA <200 Copies/mL at Week 48
Percentage of participantsGroup 1: DOR/ISLGroup 2: BIC/FTC/TAF
Percentage of Participants With HIV-1 RNA <200 Copies/mL at Week 4889.688.6
Statistical analysis
  • Group 1: DOR/ISL vs Group 2: BIC/FTC/TAF · Treatment difference: 0.83 · 95% CI -4.25 to 5.90The estimated differences, CIs and p-value for the treatment differences in percent response were calculated using the Miettinen and Nurminen method stratified by stratum with Cochran-Mantel-Haenszel (CMH) weights.
SecondaryPercentage of Participants With HIV-1 RNA <40 Copies/mL at Week 96

The Abbott RealTime PCR assay with a reliable lower limit of quantification of 40 copies/mL was used to measure the HIV-1 RNA level in blood samples obtained at each visit. The percentage of participants with HIV-1 RNA \<40 copies/mL at Week 96 was presented using the FDA Snapshot missing data approach. The final analysis for this outcome is presented here.

Time frame:
Week 96
Reported as:
Number · Percentage of participants
Percentage of Participants With HIV-1 RNA <40 Copies/mL at Week 96
Percentage of participantsGroup 1: DOR/ISLGroup 2: BIC/FTC/TAF
Percentage of Participants With HIV-1 RNA <40 Copies/mL at Week 9651.057.5
Statistical analysis
  • Group 1: DOR/ISL vs Group 2: BIC/FTC/TAF · Estimated difference: -6.74 · 95% CI -14.53 to 1.15Treatment difference for DOR/ISL group minus BIC/FTC/TAF group.
SecondaryPercentage of Participants With HIV-1 RNA <200 Copies/mL at Week 96

The Abbott RealTime PCR assay with a reliable lower limit of quantification of 40 copies/mL was used to measure the HIV-1 RNA level in blood samples obtained at each visit. The percentage of participants with HIV-1 RNA \<200 copies/mL at Week 96 was presented using the FDA Snapshot missing data approach. The final analysis for this outcome is presented here.

Time frame:
Week 96
Reported as:
Number · Percentage of participants
Percentage of Participants With HIV-1 RNA <200 Copies/mL at Week 96
Percentage of participantsGroup 1: DOR/ISLGroup 2: BIC/FTC/TAF
Percentage of Participants With HIV-1 RNA <200 Copies/mL at Week 9652.358.5
Statistical analysis
  • Group 1: DOR/ISL vs Group 2: BIC/FTC/TAF · Estimated difference: -6.41 · 95% CI -14.20 to 1.46Treatment difference for DOR/ISL group minus BIC/FTC/TAF group.
SecondaryPercentage of Participants With HIV-1 RNA <40 Copies/mL at Week 144

The Abbott RealTime PCR assay with a reliable lower limit of quantification of 40 copies/mL was used to measure the HIV-1 RNA level in blood samples obtained at each visit. The percentage of participants with HIV-1 RNA \<40 copies/mL at Week 144 was presented using the DAO missing data approach. The final analysis for this outcome is presented here.

Time frame:
Week 144
Reported as:
Number · Percentage of participants
Percentage of Participants With HIV-1 RNA <40 Copies/mL at Week 144
Percentage of participantsGroup 1: DOR/ISLGroup 2: BIC/FTC/TAF
Percentage of Participants With HIV-1 RNA <40 Copies/mL at Week 14464.182.9
Statistical analysis
  • Group 1: DOR/ISL vs Group 2: BIC/FTC/TAF · Estimated difference: -19.5 · 95% CI -38.0 to 0.2Treatment difference for DOR/ISL group minus BIC/FTC/TAF group.
SecondaryPercentage of Participants With HIV-1 RNA <200 Copies/mL at Week 144

The Abbott RealTime PCR assay with a reliable lower limit of quantification of 40 copies/mL was used to measure the HIV-1 RNA level in blood samples obtained at each visit. The percentage of participants with HIV-1 RNA \<200 copies/mL at Week 144 was presented using the DAO missing data approach. The final analysis for this outcome is presented here.

Time frame:
Week 144
Reported as:
Number · Percentage of participants
Percentage of Participants With HIV-1 RNA <200 Copies/mL at Week 144
Percentage of participantsGroup 1: DOR/ISLGroup 2: BIC/FTC/TAF
Percentage of Participants With HIV-1 RNA <200 Copies/mL at Week 14464.182.9
Statistical analysis
  • Group 1: DOR/ISL vs Group 2: BIC/FTC/TAF · Estimated difference: -19.5 · 95% CI -38.0 to 0.2Treatment difference for DOR/ISL group minus BIC/FTC/TAF group.
SecondaryMean Change From Baseline in Cluster of Differentiation 4+ (CD4+) T-Cell Counts at Week 48

Plasma CD4+ T-cell count was measured in cells/mm\^3 for baseline and at Week 48 by a central laboratory. Baseline measurements were defined as the Day 1 value of each participant. The mean change from baseline in CD4+ T-cell count at Week 48 using the Data as Observed (DAO) approach was presented. The final analysis for this outcome is presented here.

Time frame:
Baseline (Day 1) and Week 48
Reported as:
Mean · cells/mm^3
Mean Change From Baseline in Cluster of Differentiation 4+ (CD4+) T-Cell Counts at Week 48
cells/mm^3Group 1: DOR/ISLGroup 2: BIC/FTC/TAF
Mean Change From Baseline in Cluster of Differentiation 4+ (CD4+) T-Cell Counts at Week 48182.4 (162.0 to 202.7)233.5 (211.8 to 255.3)
SecondaryMean Change From Baseline in Cluster of Differentiation 4+ (CD4+) T-Cell Counts at Week 96

Plasma CD4+ T-cell count was measured in cells/mm\^3 for baseline and at Week 96 by a central laboratory. Baseline measurements were defined as the Day 1 value of each participant. The mean change from baseline in CD4+ T-cell count at Week 96 using the Data as Observed (DAO) approach was presented. The final analysis for this outcome is presented here.

Time frame:
Baseline (Day 1) and Week 96
Reported as:
Mean · cells/mm^3
Mean Change From Baseline in Cluster of Differentiation 4+ (CD4+) T-Cell Counts at Week 96
cells/mm^3Group 1: DOR/ISLGroup 2: BIC/FTC/TAF
Mean Change From Baseline in Cluster of Differentiation 4+ (CD4+) T-Cell Counts at Week 96217.05 (187.52 to 246.58)319.92 (290.53 to 349.32)
Statistical analysis
  • Group 1: DOR/ISL vs Group 2: BIC/FTC/TAF · Mean difference (final values): -91.75 · 95% CI -132.59 to -50.90Treatment Difference (DOR/ISL minus BIC/FTC/TAF)
SecondaryMean Change From Baseline in Cluster of Differentiation 4+ (CD4+) T-Cell Counts at Week 144

Plasma CD4+ T-cell count was measured in cells/mm\^3 for baseline and at Week 144 by a central laboratory. Baseline measurements were defined as the Day 1 value of each participant. The mean change from baseline in CD4+ T-cell count at Week 144 using the Data as Observed (DAO) approach was presented. The final analysis for this outcome is presented here.

Time frame:
Baseline (Day 1) and Week 144
Reported as:
Mean · cells/mm^3
Mean Change From Baseline in Cluster of Differentiation 4+ (CD4+) T-Cell Counts at Week 144
cells/mm^3Group 1: DOR/ISLGroup 2: BIC/FTC/TAF
Mean Change From Baseline in Cluster of Differentiation 4+ (CD4+) T-Cell Counts at Week 144239.6 (177.4 to 301.8)350.9 (265.7 to 436.1)
Statistical analysis
  • Group 1: DOR/ISL vs Group 2: BIC/FTC/TAF · Mean difference (final values): -111.8 · 95% CI -218.8 to -4.8Treatment Difference (DOR/ISL minus BIC/FTC/TAF)
SecondaryIncidence of Viral Resistance-Associated Substitutions (RASs) at Week 48

RASs was defined as participants with confirmed HIV-1 RNA ≥200 copies/mL and/or genotypic or phenotypic analysis of data showing evidence of resistance to the study drug administered. The number of participants who demonstrated RASs at Week 48 was presented. The final analysis for this outcome is presented here.

Time frame:
Week 48
Reported as:
Count of participants · Participants
Incidence of Viral Resistance-Associated Substitutions (RASs) at Week 48
ParticipantsGroup 1: DOR/ISLGroup 2: BIC/FTC/TAF
Incidence of Viral Resistance-Associated Substitutions (RASs) at Week 4810
SecondaryIncidence of Viral RASs at Week 96

RASs was defined as participants with confirmed HIV-1 RNA ≥200 copies/mL and/or genotypic or phenotypic analysis of data showing evidence of resistance to the study drug administered. The number of participants who demonstrated RASs at Week 96 was presented. The final analysis for this outcome is presented here.

Time frame:
Week 96
Reported as:
Count of participants · Participants
Incidence of Viral RASs at Week 96
ParticipantsGroup 1: DOR/ISLGroup 2: BIC/FTC/TAF
Incidence of Viral RASs at Week 9620
SecondaryIncidence of Viral RASs at Week 144

RASs was defined as participants with confirmed HIV-1 RNA ≥200 copies/mL and/or genotypic or phenotypic analysis of data showing evidence of resistance to the study drug administered. The number of participants who demonstrated RASs at Week 144 was presented. The final analysis for this outcome is presented here.

Time frame:
Week 144
Reported as:
Count of participants · Participants
Incidence of Viral RASs at Week 144
ParticipantsGroup 1: DOR/ISLGroup 2: BIC/FTC/TAF
Incidence of Viral RASs at Week 14420
SecondaryMean Change From Baseline in Body Weight at Week 48

Body weight was measured at baseline and at Week 48. Participants removed their shoes and wore a single layer of clothing at each measurement. Baseline measurements were defined as the Day 1 value of each participant. The mean change from baseline in body weight at Week 48 was presented. The final analysis for this outcome is presented here.

Time frame:
Baseline (Day 1) and Week 48
Reported as:
Mean · kilogram
Mean Change From Baseline in Body Weight at Week 48
kilogramGroup 1: DOR/ISLGroup 2: BIC/FTC/TAF
Mean Change From Baseline in Body Weight at Week 483.45 (2.83 to 4.06)3.32 (2.68 to 3.96)
Statistical analysis
  • Group 1: DOR/ISL vs Group 2: BIC/FTC/TAF · ANCOVA · p = 0.73 · Treatment difference: 0.15 · 95% CI -0.71 to 1.02ANCOVA model was used to generate treatment difference and the associated 95%CI. The 95% CIs for treatment difference were calculated from ANCOVA models with terms for baseline weight, sex, race, stratum, and treatment.
SecondaryMean Change From Baseline in Body Weight at Week 96

Body weight was measured at baseline and at Week 96. Participants removed their shoes and wore a single layer of clothing at each measurement. Baseline measurements were defined as the Day 1 value of each participant. The mean change from baseline in body weight at Week 96 was presented. The final analysis for this outcome is presented here.

Time frame:
Baseline (Day 1) and Week 96
Reported as:
Mean · kilogram
Mean Change From Baseline in Body Weight at Week 96
kilogramGroup 1: DOR/ISLGroup 2: BIC/FTC/TAF
Mean Change From Baseline in Body Weight at Week 963.31 (2.45 to 4.18)4.13 (3.15 to 5.11)
Statistical analysis
  • Group 1: DOR/ISL vs Group 2: BIC/FTC/TAF · ANCOVA · p = 0.268 · Estimated difference: -0.74 · 97% CI -2.19 to 0.71The CIs for treatment difference were calculated from ANCOVA models with terms for baseline weight, sex, race, stratum and treatment. The CIs at week 96 is 97% corresponds to a 1-sided Type 1 error of 0.015.
SecondaryMean Change From Baseline in Body Weight at Week 144

Body weight was measured at baseline and at Week 144. Participants removed their shoes and wore a single layer of clothing at each measurement. Baseline measurements were defined as the Day 1 value of each participant. The mean change from baseline in body weight at Week 144 was presented. The final analysis for this outcome is presented here.

Time frame:
Baseline (Day 1) and Week 144
Reported as:
Mean · kilogram
Mean Change From Baseline in Body Weight at Week 144
kilogramGroup 1: DOR/ISLGroup 2: BIC/FTC/TAF
Mean Change From Baseline in Body Weight at Week 1444.55 (2.40 to 6.70)3.55 (-1.46 to 8.56)
Statistical analysis
  • Group 1: DOR/ISL vs Group 2: BIC/FTC/TAF · Estimated difference: 1.08 · 95% CI -4.07 to 6.24The CIs for treatment difference were calculated from ANCOVA models with terms for baseline weight, sex, race, stratum and treatment.
SecondaryPercentage of Participants Who Experienced an Adverse Event (AE)

An AE was any untoward medical occurrence in a study participant administered a study drug, which does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of the study drug whether or not it is considered related to the study drug. The percentage of participants who experienced at least one or more AEs is presented. Per protocol, pregnancy-related AEs collected for enrolled participants are reported separately and are presented in the AE module. The final analysis for this outcome is presented here.

Time frame:
Up to approximately 47 months
Reported as:
Number · Percentage of participants
Percentage of Participants Who Experienced an Adverse Event (AE)
Percentage of participantsGroup 1: DOR/ISLGroup 2: BIC/FTC/TAF
Percentage of Participants Who Experienced an Adverse Event (AE)96.694.0
SecondaryPercentage of Participants Who Discontinued Study Treatment Due to an AE

An AE was any untoward medical occurrence in a study participant administered a study drug, which does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of the study drug whether or not it is considered related to the study drug. The percentage of participants who discontinued study intervention due to an AE is presented. Per protocol, pregnancy-related AEs collected for enrolled participants are reported separately and are presented in the AE module. The final analysis for this outcome is presented here.

Time frame:
Up to approximately 38 months
Reported as:
Number · Percentage of participants
Percentage of Participants Who Discontinued Study Treatment Due to an AE
Percentage of participantsGroup 1: DOR/ISLGroup 2: BIC/FTC/TAF
Percentage of Participants Who Discontinued Study Treatment Due to an AE14.19.0

Adverse events

Collected over Up to approximately 47 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Group 1: DOR/ISL Base Study Week 0 - Week 482/298 (0.7%)19/298 (6.4%)146/298 (49%)
Group 1: DOR/ISL Base Study Week 48-Week 960/266 (0%)14/266 (5.3%)115/266 (43.2%)
Group 1: DOR/ISL Base Study Week 96-Week 1440/146 (0%)3/146 (2.1%)42/146 (28.8%)
Group 2: BIC/FTC/TAF Base Study Week 0 - Week 480/301 (0%)16/299 (5.4%)141/299 (47.2%)
Group 2: BIC/FTC/TAF Base Study Week 48 - Week 960/267 (0%)13/267 (4.9%)124/267 (46.4%)
Group 2: BIC/FTC/TAF Base Study Week 96 - Week 1440/143 (0%)1/143 (0.7%)37/143 (25.9%)
Group 1: DOR/ISL Open-Label Extension Week 144-Week 1680/21 (0%)0/21 (0%)3/21 (14.3%)
Group 2: BIC/FTC/TAF Open-Label Extension Week 144 - Week 1680/27 (0%)0/27 (0%)2/27 (7.4%)
Group 1: DOR/ISL Post-Treatment Follow-Up1/112 (0.9%)3/112 (2.7%)8/112 (7.1%)
Group 2: BIC/FTC/TAF Post-Treatment Follow-Up0/128 (0%)1/128 (0.8%)2/128 (1.6%)
Most frequent serious events
Showing 10 of 70
Most frequent serious events
EventGroup 1: DOR/ISL Base Study Week 0 - Week 48Group 1: DOR/ISL Base Study Week 48-Week 96Group 1: DOR/ISL Base Study Week 96-Week 144Group 2: BIC/FTC/TAF Base Study Week 0 - Week 48Group 2: BIC/FTC/TAF Base Study Week 48 - Week 96Group 2: BIC/FTC/TAF Base Study Week 96 - Week 144Group 1: DOR/ISL Open-Label Extension Week 144-Week 168Group 2: BIC/FTC/TAF Open-Label Extension Week 144 - Week 168Group 1: DOR/ISL Post-Treatment Follow-UpGroup 2: BIC/FTC/TAF Post-Treatment Follow-Up
Drug hypersensitivityImmune system disorders3/2980/2660/1461/2990/2670/1430/210/270/1120/128
Pneumonia pneumococcalInfections and infestations0/2980/2660/1460/2990/2670/1430/210/271/1120/128
Stab woundInjury, poisoning and procedural complications0/2980/2660/1460/2990/2670/1430/210/271/1120/128
DepressionPsychiatric disorders0/2980/2660/1460/2990/2670/1430/210/271/1120/128
Febrile convulsionNervous system disorders0/2980/2660/1460/2990/2670/1430/210/270/1121/128
Gestational hypertensionPregnancy, puerperium and perinatal conditions0/2980/2660/1460/2990/2670/1430/210/270/1121/128
Major depressionPsychiatric disorders0/2980/2660/1460/2990/2671/1430/210/270/1120/128
DiverticulitisInfections and infestations0/2980/2661/1460/2990/2670/1430/210/270/1120/128
Scrotal abscessInfections and infestations0/2980/2661/1460/2990/2670/1430/210/270/1120/128
Scrotal cellulitisInfections and infestations0/2980/2661/1460/2990/2670/1430/210/270/1120/128
Most frequent other events
Most frequent other events
EventGroup 1: DOR/ISL Base Study Week 0 - Week 48Group 1: DOR/ISL Base Study Week 48-Week 96Group 1: DOR/ISL Base Study Week 96-Week 144Group 2: BIC/FTC/TAF Base Study Week 0 - Week 48Group 2: BIC/FTC/TAF Base Study Week 48 - Week 96Group 2: BIC/FTC/TAF Base Study Week 96 - Week 144Group 1: DOR/ISL Open-Label Extension Week 144-Week 168Group 2: BIC/FTC/TAF Open-Label Extension Week 144 - Week 168Group 1: DOR/ISL Post-Treatment Follow-UpGroup 2: BIC/FTC/TAF Post-Treatment Follow-Up
Lymphocyte count decreasedInvestigations27/29864/26625/14612/29955/26724/1433/210/270/1120/128
COVID-19Infections and infestations42/29820/2662/14647/29929/2673/1430/211/270/1121/128
HeadacheNervous system disorders31/29813/2662/14634/29913/2672/1430/210/271/1120/128
CD4 lymphocytes decreasedInvestigations2/29828/26612/1461/29925/26714/1430/211/270/1120/128
DiarrhoeaGastrointestinal disorders26/2986/2662/14620/2995/2672/1430/210/270/1121/128
Weight increasedInvestigations19/2982/2660/14618/2998/2671/1430/211/271/1120/128
Accidental overdoseInjury, poisoning and procedural complications17/2987/2663/14616/29917/2671/1430/210/270/1120/128
InsomniaPsychiatric disorders13/2984/2661/14619/2993/2671/1430/210/272/1120/128
Upper respiratory tract infectionInfections and infestations15/29814/2664/14615/29911/2674/1430/210/277/1120/128
ArthralgiaMusculoskeletal and connective tissue disorders16/29811/2662/14614/2995/2670/1430/210/270/1120/128

Baseline characteristics

All randomized participants.

Age, Continuous
Age, Continuous(Years)Group 1: DOR/ISLGroup 2: BIC/FTC/TAFTotal
Mean34.7 ± 11.035.7 ± 10.935.2 ± 10.9
Sex: Female, Male
Sex: Female, Male(Participants)Group 1: DOR/ISLGroup 2: BIC/FTC/TAFTotal
Female7771148
Male221230451
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Group 1: DOR/ISLGroup 2: BIC/FTC/TAFTotal
Hispanic or Latino123112235
Not Hispanic or Latino171184355
Unknown or Not Reported459
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Group 1: DOR/ISLGroup 2: BIC/FTC/TAFTotal
American Indian or Alaska Native224
Asian162036
Native Hawaiian or Other Pacific Islander000
Black or African American8690176
White171169340
More than one race231942
Unknown or Not Reported011
Baseline Human Immunodeficiency Virus (HIV)-1 Ribonucleic Acid (RNA) Level
Baseline Human Immunodeficiency Virus (HIV)-1 Ribonucleic Acid (RNA) Level(Participants)Group 1: DOR/ISLGroup 2: BIC/FTC/TAFTotal
≤100,000 copies/mL244239483
>100,000 copies/mL5460114
Missing022
Baseline Cluster of Differentiation 4+ (CD4+) T-Cell Count
Baseline Cluster of Differentiation 4+ (CD4+) T-Cell Count(Participants)Group 1: DOR/ISLGroup 2: BIC/FTC/TAFTotal
<200 cells/mm^36160121
≥200 cells/mm^3237239476
Missing022
08

Study locations

95 sites
  • University of Alabama at Birmingham 1917 Research Clinic ( Site 5610)
    Birmingham, Alabama 35222, United States
  • Pueblo Family Physicians ( Site 5606)
    Phoenix, Arizona 85015, United States
  • Ruane Clinical Research Group, Inc. ( Site 5624)
    Los Angeles, California 90036, United States
  • Midway Immunology and Research ( Site 5622)
    Ft. Pierce, Florida 34982, United States
  • The Kinder Medical Group ( Site 5615)
    Miami, Florida 33133, United States
  • Floridian Clinical Research, LLC ( Site 5625)
    Miami Lakes, Florida 33016, United States
  • Orlando Immunology Center ( Site 5613)
    Orlando, Florida 32803, United States
  • CAN Community Health ( Site 5627)
    Sarasota, Florida 34237, United States
  • Triple O Research Institute, P.A. ( Site 5621)
    West Palm Beach, Florida 33407, United States
  • Columbus Regional Research Institute ( Site 5616)
    Columbus, Georgia 31904, United States
  • Infectious Disease Specialists Of Atlanta PC ( Site 5608)
    Decatur, Georgia 30033, United States
  • Hennepin Healthcare-Hennepin Healthcare-ID ( Site 5633)
    Minneapolis, Minnesota 55415, United States
  • Kansas City CARE Clinic ( Site 5607)
    Kansas City, Missouri 64111, United States
  • University of Pennsylvania ( Site 5630)
    Philadelphia, Pennsylvania 19104, United States
  • Saint Hope Foundation, Inc. ( Site 5629)
    Bellaire, Texas 77401, United States
  • North Texas ID Consultants, PA ( Site 5604)
    Dallas, Texas 75246, United States
  • Texas Centers for Infectious Disease Associates P.A. ( Site 5619)
    Fort Worth, Texas 76104, United States
  • Helios Salud S.A. ( Site 5802)
    Buenos Aires, Buenos Aires F.D. C1141ACG, Argentina
  • IDEAA Foundation ( Site 5807)
    Buenos Aires, Buenos Aires F.D. C1405CKC, Argentina
  • Fundación Huesped ( Site 5801)
    C.a.b.a, Buenos Aires F.D. C1202ABB, Argentina
  • Instituto CAICI ( Site 5803)
    Rosario, Santa Fe Province S2000PBJ, Argentina
  • Instituto Oulton ( Site 5804)
    Córdoba, X5000JJS, Argentina
  • Hamilton Health Sciences- Urgent Care Centre-SIS Clinic ( Site 5703)
    Hamilton, Ontario L8S 14K, Canada
  • Toronto General Hospital - University Health Network ( Site 5705)
    Toronto, Ontario M5G 2N2, Canada
  • Clinique Medicale L Actuel ( Site 5714)
    Montreal, Quebec H2L 4P9, Canada
  • McGill University Health Center - Research Institute-CVIS Clinical Research Unit ( Site 5702)
    Montreal, Quebec H4A 3J1, Canada
  • Hospital Dr. Hernan Henriquez Aravena ( Site 5905)
    Temuco, Araucania 4781151, Chile
  • Clinica Universidad Catolica del Maule ( Site 5909)
    Talca, Maule Region 3460000, Chile
  • Clinica Arauco Salud ( Site 5900)
    Santiago, Region M. de Santiago 7560994, Chile
  • Hospital Clinico de la Universidad Catolica ( Site 5903)
    Santiago, Region M. de Santiago 8331150, Chile
  • Fundacion Arriaran ( Site 5901)
    Santiago, Region M. de Santiago 8360159, Chile
  • Centro Cardiovascular Cardiosur ( Site 5907)
    Santiago, Region M. de Santiago 8910259, Chile
  • Hospital Universitario San Ignacio ( Site 6005)
    Bogotá, Bogota D.C. 110231, Colombia
  • Clinica Colsanitas S.A. Sede Clinica Universitaria Colombia ( Site 6006)
    Bogotá, Bogota D.C. 111321, Colombia
  • Fundacion Valle del Lili ( Site 6001)
    Cali, Valle del Cauca Department 760032, Colombia
  • A.P.H. Paris. Hopital Bichat Claude Bernard ( Site 6124)
    Paris, Ain 75018, France
  • Hopital de la Croix-Rousse ( Site 6127)
    Lyon, Auvergne-Rhône-Alpes 69004, France
  • Centre Hospitalier Regional du Orleans ( Site 6108)
    Orléans, Centre-Val de Loire 45000, France
  • Hopital Francois Mitterrand ( Site 6119)
    Dijon, Cote-d Or 21079, France
  • CHU de Bordeaux. Hopital Pellegrin ( Site 6116)
    Bordeaux, Gironde 33076, France
  • Centre Hospitalier de Tourcoing ( Site 6100)
    Tourcoing, Nord 59208, France
  • Hopital Avicenne ( Site 6102)
    Bobigny, Seine-Saint-Denis 93000, France
  • A.P.H. Paris, Hopital Saint Louis ( Site 6114)
    Paris, 75010, France
  • Hopital Saint-Antoine ( Site 6113)
    Paris, 75012, France
  • Hopital Pitie Salpetriere ( Site 6111)
    Paris, 75013, France
  • Universitaetsklinik Freiburg ( Site 6206)
    Freiburg im Breisgau, Baden-Wurttemberg 79106, Germany
  • Klinikum der LMU München ( Site 6204)
    Munich, Bavaria 80336, Germany
  • MVZ Munchen am Goetheplatz ( Site 6202)
    Munich, Bavaria 80337, Germany
  • Infektiologikum ( Site 6201)
    Frankfurt am Main, Hesse 60596, Germany
  • Universitaetsklinikum Bonn ( Site 6200)
    Bonn, North Rhine-Westphalia 53127, Germany
  • EPIMED- Ges. f. epidemiolog. u. klin. Forschung in der Medizin mbH ( Site 6208)
    Berlin, 10787, Germany
  • Universitaetsklinikum Hamburg- Eppendorf (UKE) ( Site 6210)
    Hamburg, 20246, Germany
  • Rambam Medical Center ( Site 6701)
    Haifa, 3109601, Israel
  • Hadassah Ein Kerem Medical Center ( Site 6702)
    Jerusalem, 9112001, Israel
  • Chaim Sheba Medical Center. ( Site 6704)
    Ramat Gan, 5265601, Israel
  • Kaplan Medical Center ( Site 6700)
    Rehovot, 7610001, Israel
  • Sourasky Medical Center ( Site 6705)
    Tel Aviv, 64239, Israel
  • A.O.R.N. dei Colli - Ospedale Cotugno ( Site 6407)
    Naples, Campania 80131, Italy
  • Azienda Ospedaliero Universitaria di Modena Policlinico ( Site 6404)
    Modena, Emilia-Romagna 41124, Italy
  • ASST Papa Giovanni XXIII ( Site 6411)
    Bergamo, Lombardy 24127, Italy
  • Ospedale San Gerardo ASST Monza ( Site 6412)
    Monza, Monza E Brianza 20900, Italy
  • Ospedale Amedeo di Savoia ( Site 6414)
    Turin, Piedmont 10149, Italy
  • Fondazione IRCCS Ca' Granda-Ospedale Maggiore Policlinico ( Site 6401)
    Milan, 20122, Italy
  • Salute San Raffaele ( Site 6402)
    Milan, 20127, Italy
  • Azienda Ospedaliera San Paolo ( Site 6403)
    Milan, 20142, Italy
  • ASST Fatebenefratelli-Ospedale Sacco ( Site 6400)
    Milan, 20157, Italy
  • IRCCS Policlinico San Matteo ( Site 6410)
    Pavia, 27100, Italy
  • Azienda USL di Pescara-Presidio Ospedaliero di Pescara ( Site 6413)
    Pescara, 65129, Italy
  • Istituto Nazionale per Le Malattie Infettive Lazzaro Spallanzani ( Site 6405)
    Roma, 00149, Italy
  • National Hospital Organization Nagoya Medical Center ( Site 6903)
    Nagoya, Aichi-ken 460-0001, Japan
  • Kumamoto University Hospital ( Site 6905)
    Kumamoto, 860-8556, Japan
  • National Hospital Organization - Osaka National Hospital - Institute For Clinical Research ( Site 69
    Osaka, 540-0006, Japan
  • Tokyo Medical University Hospital ( Site 6904)
    Tokyo, 160-0023, Japan
  • Center Hospital of the National Center for Global Health and Medicine ( Site 6901)
    Tokyo, 162-8655, Japan
  • JOSHA Research ( Site 6605)
    Bloemfontein, Free State 9301, South Africa
  • Chris Hani Baragwanath Hospital - ICU ( Site 6608)
    Johannesburg, Gauteng 1862, South Africa
  • Wits Health Consortium. Clinical HIV Research Unit ( Site 6614)
    Johannesburg, Gauteng 2041, South Africa
  • Ezintsha ( Site 6609)
    Johannesburg, Gauteng 2193, South Africa
  • Wentworth Hospital ( Site 6607)
    Durban, KwaZulu-Natal 4052, South Africa
  • Family Clinical Research Unit (Fam-Cru)-Adult Infectious Diseases ( Site 6617)
    Cape Town, Western Cape 7500, South Africa
  • Desmond Tutu HIV Foundation Clinical Trial Unit ( Site 6613)
    Cape Town, Western Cape 7925, South Africa
  • Be Part Yoluntu Centre ( Site 6603)
    Mbekweni, Paarl, Western Cape 7646, South Africa
  • Hospital General de Elche ( Site 6308)
    Elche, Alicante 03202, Spain
  • Hospital Universitari Germans Trias i Pujol ( Site 6301)
    Badalona, Barcelona 08916, Spain
  • Hospital Universitari de Bellvitge ( Site 6312)
    LHospitalet de Llobregat, Barcelona 08907, Spain
  • Hospital Vall D Hebron ( Site 6302)
    Barcelona, Catalonia 08035, Spain
  • Hospital Clinic i Provincial ( Site 6300)
    Barcelona, Catalonia 08036, Spain
  • Hospital General Universitario Gregorio Maranon ( Site 6303)
    Madrid, 28007, Spain
  • Hospital Universitario Fundacion Jimenez Diaz ( Site 6307)
    Madrid, 28040, Spain
  • Hospital Universitario 12 de Octubre ( Site 6305)
    Madrid, 28041, Spain
  • Hospital Universitario La Paz ( Site 6304)
    Madrid, 28046, Spain
  • Hospital Universitario Virgen de la Victoria ( Site 6309)
    Málaga, 29010, Spain
  • Kaohsiung Veterans General Hospital ( Site 7102)
    Kaohsiung City, 81362, Taiwan
  • National Cheng Kung University Hospital ( Site 7101)
    Tainan, 70403, Taiwan
  • National Taiwan University Hospital ( Site 7100)
    Taipei, 100, Taiwan
09

References and documents

Publications

  • Rockstroh JK, Paredes R, Cahn P, Molina JM, Sokhela SM, Hinestrosa F, Kassim S, Cunningham D, Ghosn J, Bogner JR, Gatanaga H, Asante-Appiah E, Zhang Y, Nwoke U, Klopfer SO, Eves K, Squires K, Correll T, Fox MC, Pisculli ML. Doravirine/Islatravir (100/0.75 mg) Once-Daily Compared With Bictegravir/Emtricitabine/Tenofovir Alafenamide as Initial HIV-1 Treatment: 48-Week Results From a Phase 3, Randomized, Controlled, Double-Blind, Noninferiority Trial. Clin Infect Dis. 2025 Sep 16;81(2):322-332. doi: 10.1093/cid/ciaf077. PubMed 40079835 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2020 to primary completion in Nov 2022, 32 months.

Results were first posted in Nov 2023, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 15, 2020
First posted
Jan 18, 2020
StartActual
Feb 28, 2020
Primary completionActual
Nov 17, 2022
CompletionActual
Jan 29, 2025
Results first posted
Nov 21, 2023
Last update
Jun 3, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 3, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04233879
Responsible party
Sponsor
First posted
Jan 18, 2020
Start date
Feb 28, 2020
Primary completion
Nov 17, 2022
Completion
Jan 29, 2025
Results posted
Nov 21, 2023
Last update
Jun 3, 2026

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Doravirine · Islatravir

Start the discussion